Free Trial
→ SpaceX is offering you shares. Don't take them. (From Behind the Markets) (Ad)tc pixel Free TSHA Stock Alerts

Taysha Gene Therapies (TSHA) Short Interest Ratio & Short Volume

Taysha Gene Therapies logo
$5.44 -0.06 (-1.15%)
Closing price 03:59 PM Eastern
Extended Trading
$5.44 0.00 (-0.04%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Taysha Gene Therapies Short Interest Overview

As of May 15, 2026, Taysha Gene Therapies (TSHA) had a short interest of 36.70 million shares sold short, representing 13.27% of the public float. This marks a -8.36% decrease in short interest since the prior report. The short interest ratio (days to cover) is 15.1, meaning it would take 15.1 days of the average trading volume of 2.63 million shares to cover all short positions.

Current Short Interest
36,701,725 shares
Previous Short Interest
40,051,105 shares
Change Vs. Previous Month
-8.36%
Dollar Volume Sold Short
$218.74 million
Short Interest Ratio
15.1 Days to Cover
Last Record Date
May 15, 2026
Outstanding Shares
287,361,000 shares
Short Percent of Float
13.27%
Today's Trading Volume
926,481 shares
Average Trading Volume
2,632,981 shares
Today's Volume Vs. Average
35%
Short Selling Taysha Gene Therapies?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Taysha Gene Therapies and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

TSHA Short Interest Over Time

TSHA Days to Cover Over Time

TSHA Percentage of Float Shorted Over Time

Taysha Gene Therapies Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/15/202636,701,725 shares $218.74 million -8.4%13.3%15.09 $5.96
4/30/202640,051,105 shares $255.93 million +2.9%14.5%14 $6.39
11/14/202548,083,858 shares $198.59 million +8.4%18.2%10.89 $4.13
10/31/202544,369,833 shares $220.07 million +5.7%16.8%11.57 $4.96
10/15/202541,980,000 shares $224.17 million -15.3%16.0%7 $5.34
9/30/202549,550,000 shares $162.03 million +14.3%N/A8.7 $3.27
9/15/202543,360,000 shares $130.95 million +6.3%N/A13.7 $3.02
8/31/202540,780,000 shares $119.08 million +12.0%15.5%13.1 $2.92
8/15/202536,410,000 shares $107.05 million -4.7%N/A10.5 $2.94
7/31/202538,210,000 shares $104.31 million -13.1%18.5%10.6 $2.73
7/15/202543,960,000 shares $110.34 million +2,952.8%N/A11.4 $2.51
6/30/20251,440,000 shares $3.33 million -95.7%0.7%2.3 $2.31
6/15/202533,270,000 shares $84.51 million +4.0%16.1%8.8 $2.54
5/31/202531,980,000 shares $86.67 million +21.9%16.0%9.4 $2.71
5/15/202526,240,000 shares $67.17 million +0.7%13.2%9.5 $2.56
4/30/202526,060,000 shares $50.56 million +12.6%N/A10.8 $1.94
4/15/202523,150,000 shares $29.40 million +7.0%11.6%10.8 $1.27
3/31/202521,630,000 shares $30.07 million -14.3%10.8%9.8 $1.39
3/15/202525,250,000 shares $43.43 million -1.1%12.7%12.5 $1.72
2/28/202525,530,000 shares $40.85 million +1.8%12.8%10.9 $1.60
2/15/202525,090,000 shares $40.90 million +4.2%12.6%8.1 $1.63
1/31/202524,080,000 shares $36.12 million +0.5%N/A5.7 $1.50
1/15/202523,950,000 shares $39.04 million -7.5%N/A5.4 $1.63
12/31/202425,880,000 shares $44.77 million +18.3%N/A6 $1.73
12/15/202421,880,000 shares $45.29 million +39.6%N/A5.1 $2.07
11/30/202415,670,000 shares $50.77 million -0.5%N/A3.8 $3.24
11/15/202415,750,000 shares $32.45 million -10.7%N/A4.4 $2.06
10/31/202417,640,000 shares $29.81 million -14.8%N/A8.1 $1.69
10/15/202420,700,000 shares $40.37 million +0.3%N/A13.9 $1.95
9/30/202420,640,000 shares $41.49 million +4.1%N/A13.7 $2.01
9/15/202419,830,000 shares $45.41 million -8.5%N/A9.5 $2.29
8/31/202421,660,000 shares $48.52 million +4.2%N/A9.5 $2.24
8/15/202420,780,000 shares $47.59 million -10.5%N/A8.3 $2.29
7/31/202423,210,000 shares $51.29 million +11.5%N/A8.9 $2.21
7/15/202420,810,000 shares $50.78 million +54.7%N/A7.9 $2.44
6/30/202413,450,000 shares $30.13 million -8.6%N/A4.9 $2.24
6/15/202414,720,000 shares $58.44 million -8.7%N/A6.3 $3.97
5/31/202416,120,000 shares $55.29 million -5.4%N/A6.7 $3.43
5/15/202417,040,000 shares $52.99 million +0.8%N/A6.4 $3.11
4/30/202416,910,000 shares $41.09 million +5.2%N/A6.1 $2.43
Read this warning immediately (Ad)

Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel

Read Porter Stansberry's full breakdown and protect your wealth now
4/15/202416,070,000 shares $42.75 million -5.4%N/A5.9 $2.66
3/31/202416,990,000 shares $48.76 million +7.5%N/A6.1 $2.87
3/15/202415,810,000 shares $36.36 million +13.9%N/A6 $2.30
2/29/202413,880,000 shares $43.86 million -14.9%N/A6.3 $3.16
2/15/202416,300,000 shares $25.92 million -2.9%N/A8.3 $1.59
1/31/202416,780,000 shares $25.51 million -4.1%N/A8 $1.52
1/15/202417,490,000 shares $27.98 million -0.2%N/A7.8 $1.60
12/31/202317,530,000 shares $31.03 million +2.3%N/A7.8 $1.77
12/15/202317,130,000 shares $27.92 million +6.0%N/A8.2 $1.63
11/30/202316,160,000 shares $28.44 million +15.8%N/A7.6 $1.76
11/15/202313,950,000 shares $23.44 million +42.9%N/A5.6 $1.68
10/31/20239,760,000 shares $22.84 million -2.6%N/A1.8 $2.34
10/15/202310,020,000 shares $22.65 million -6.1%N/A1.9 $2.26
9/30/202310,670,000 shares $33.72 million +7.5%N/A2.1 $3.16
9/15/20239,930,000 shares $32.67 million +34.9%N/A2.1 $3.29
8/31/20237,360,000 shares $23.55 million +902.0%N/A1.6 $3.20
8/15/2023734,500 shares $1.60 million -33.2%3.9%0.2 $2.18
7/31/20231,100,000 shares $740.52 thousand -1.8%3.0%4.4 $0.67
7/15/20231,120,000 shares $773.92 thousand -12.5%3.1%4.3 $0.69
6/30/20231,280,000 shares $846.08 thousand -10.5%3.5%4 $0.66
6/15/20231,430,000 shares $1.09 million +16.3%3.8%3.7 $0.77
5/31/20231,230,000 shares $859.65 thousand +3.4%3.4%3.2 $0.70
5/15/20231,190,000 shares $824.79 thousand -31.2%3.2%3 $0.69
4/30/20231,730,000 shares $1.34 million +6.1%4.7%4.1 $0.78
4/15/20231,630,000 shares $1.42 million -15.5%4.5%2.9 $0.87
3/31/20231,930,000 shares $1.54 million -18.2%5.4%3.5 $0.80
3/15/20232,360,000 shares $2.07 million -11.6%6.5%4.4 $0.88
2/28/20232,670,000 shares $2.70 million +19.7%7.3%4.7 $1.01
2/15/20232,230,000 shares $2.41 million +2.3%6.1%3.7 $1.08
1/31/20232,180,000 shares $3.58 million +26.7%6.0%2.7 $1.64
1/15/20231,720,000 shares $3.96 million +25.6%4.7%0.7 $2.30
12/30/20221,370,000 shares $3.10 million +48.0%3.8%0.5 $2.26
12/15/2022925,700 shares $2.13 million +12.3%2.5%0.4 $2.30
11/30/2022824,500 shares $1.82 million -38.5%3.8%0.3 $2.21
11/15/20221,340,000 shares $2.95 million -19.8%6.3%0.6 $2.20
10/31/20221,670,000 shares $2.87 million +73.8%11.3%0.8 $1.72
10/15/2022960,700 shares $1.53 million +8.0%4.1%0.6 $1.59
9/30/2022889,600 shares $1.72 million -5.2%3.8%8.5 $1.93
9/15/2022938,700 shares $2.92 million +5.2%4.0%6.2 $3.11
8/31/2022892,600 shares $2.82 million +3.5%3.8%5.3 $3.16
8/15/2022862,300 shares $3.74 million -7.2%3.7%4 $4.34
7/31/2022929,100 shares $3.78 million -10.7%4.1%3.8 $4.07
7/15/20221,040,000 shares $4.43 million -13.3%4.5%3.9 $4.26
6/30/20221,200,000 shares $4.46 million -26.4%5.2%3.8 $3.72
6/15/20221,630,000 shares $4.91 million -3.6%7.1%4.9 $3.01
5/31/20221,690,000 shares $4.31 million -4.5%7.7%6 $2.55
5/15/20221,770,000 shares $6.09 million +18.0%8.1%6.5 $3.44
4/30/20221,500,000 shares $5.49 million +19.1%7.2%5.4 $3.66
4/15/20221,260,000 shares $6.98 million -64.6%6.1%4.5 $5.54
3/31/20223,560,000 shares $23.21 million +4.1%17.1%15.3 $6.52
Goldman Sachs just told you what to buy (most people missed it) (Ad)

Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel

See the stock positioned to solve AI's biggest power crisis
3/15/20223,420,000 shares $18.30 million +0.6%16.4%15.9 $5.35
2/28/20223,400,000 shares $21.66 million -6.6%16.4%15.3 $6.37
2/15/20223,640,000 shares $28.50 million +10.0%17.5%17 $7.83
1/31/20223,310,000 shares $26.31 million +9.2%15.9%16.2 $7.95
1/15/20223,030,000 shares $28.88 million +0.7%13.9%15.6 $9.53
12/31/20213,010,000 shares $35.07 million +18.0%14.3%16.8 $11.65
12/15/20212,550,000 shares $36.31 million -1.5%12.1%14.9 $14.24
11/30/20212,590,000 shares $33.62 million +1.2%12.3%17.7 $12.98
11/15/20212,560,000 shares $37.12 million +6.7%12.2%18.4 $14.50
10/29/20212,400,000 shares $37.54 million -4.4%11.0%19.7 $15.64
10/15/20212,510,000 shares $44.88 million -11.3%11.6%27 $17.88
9/30/20212,830,000 shares $52.69 million +3.7%13.0%28.3 $18.62
9/15/20212,730,000 shares $57.00 million No Change12.6%17.6 $20.88
8/31/20212,730,000 shares $54.27 million -0.4%12.7%16.6 $19.88
8/13/20212,740,000 shares $47.62 million -0.7%12.6%14.3 $17.38
7/30/20212,760,000 shares $47.72 million +10.8%12.8%14.1 $17.29
7/15/20212,490,000 shares $48.88 million +31.1%11.6%12.9 $19.63
6/30/20211,900,000 shares $40.28 million +37.7%9.8%9.9 $21.20
6/15/20211,380,000 shares $35.85 million -11.5%6.9%9.7 $25.98

TSHA Short Interest - Frequently Asked Questions

Short interest is the volume of Taysha Gene Therapies shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 36,701,725 shares of TSHA short. 13.27% of Taysha Gene Therapies' shares are currently sold short. Learn More on Taysha Gene Therapies' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TSHA shares currently have a short interest ratio of 15.1. Learn More on Taysha Gene Therapies's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.27% of Taysha Gene Therapies' floating shares are currently sold short.

Taysha Gene Therapies saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 36,701,725 shares, a decline of 8.4% from the previous total of 40,051,105 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

13.27% of Taysha Gene Therapies' shares are currently sold short. Here is how the short interest of companies compare to Taysha Gene Therapies: Howard Hughes Holdings Inc. (9.30%), Kymera Therapeutics, Inc. (14.48%), Lantheus Holdings, Inc. (10.06%), Protagonist Therapeutics, Inc. (11.96%), Spyre Therapeutics, Inc. (16.96%), Mirum Pharmaceuticals, Inc. (15.70%), PTC Therapeutics, Inc. (13.06%), Rhythm Pharmaceuticals, Inc. (12.84%), Cogent Biosciences, Inc. (7.04%), Centessa Pharmaceuticals PLC Sponsored ADR (1.72%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($80.71 billion), Invesco QQQ ($47.96 billion), iShares Russell 2000 ETF ($22.13 billion), Western Digital Corporation ($14.35 billion), Sandisk Corporation ($12.86 billion), Salesforce Inc. ($10.89 billion), Nebius Group N.V. ($9.92 billion), SPDR S&P Biotech ETF ($9.72 billion), Lumentum Holdings Inc. ($8.89 billion), and iShares 20+ Year Treasury Bond ETF ($8.18 billion). View all of the most shorted stocks.

Short selling TSHA is an investing strategy that aims to generate trading profit from Taysha Gene Therapies as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Taysha Gene Therapies occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TSHA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TSHA, twice per month. The most recent reporting period available is May, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like TSHA:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:TSHA) was last updated on 6/8/2026 by MarketBeat.com Staff.
From Our Partners
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...
Porter & Company | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Important SpaceX PREDICTION
The biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian s...
Banyan Hill Publishing | Sponsoredtc pixel
Your name isn't on our protected list yet
I checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...
American Alternative | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel